Literature DB >> 26771003

A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis.

Anuradha Kumar1, Ana Guardia2, Gonzalo Colmenarejo3, Esther Pérez2, Ruben R Gonzalez2, Pedro Torres2, David Calvo2, Ruben M Gómez2, Fátima Ortega2, Elena Jiménez2, Raquel C Gabarro2, Joaquín Rullás2, Lluis Ballell2, David R Sherman1,4.   

Abstract

Antifolates are widely used to treat several diseases but are not currently used in the first-line treatment of tuberculosis, despite evidence that some of these molecules can target Mycobacterium tuberculosis (Mtb) bacilli in vitro. To identify new antifolate candidates for animal-model efficacy studies of tuberculosis, we paired knowledge and tools developed in academia with the infrastructure and chemistry resources of a large pharmaceutical company. Together we curated a focused library of 2508 potential antifolates, which were then tested for activity against live Mtb. We identified 210 primary hits, confirmed the on-target activity of potent compounds, and now report the identification and characterization of 5 hit compounds, representative of 5 different chemical scaffolds. These antifolates have potent activity against Mtb and represent good starting points for improvement that could lead to in vivo efficacy studies.

Entities:  

Keywords:  antifolate; dihydrofolate reductase; trimetrexate; tuberculosis

Year:  2015        PMID: 26771003      PMCID: PMC4707675          DOI: 10.1021/acsinfecdis.5b00063

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  36 in total

1.  Ligand efficiency: a useful metric for lead selection.

Authors:  Andrew L Hopkins; Colin R Groom; Alexander Alex
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

2.  A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry.

Authors:  Mahmud Kajbaf; Raffaele Longhi; Dino Montanari; Federica Vinco; Monica Rigo; Stefano Fontana; Kevin D Read
Journal:  Drug Metab Lett       Date:  2011-01

3.  Physicochemical properties of antibacterial compounds: implications for drug discovery.

Authors:  Rosemarie O'Shea; Heinz E Moser
Journal:  J Med Chem       Date:  2008-02-09       Impact factor: 7.446

4.  Thousands of chemical starting points for antimalarial lead identification.

Authors:  Francisco-Javier Gamo; Laura M Sanz; Jaume Vidal; Cristina de Cozar; Emilio Alvarez; Jose-Luis Lavandera; Dana E Vanderwall; Darren V S Green; Vinod Kumar; Samiul Hasan; James R Brown; Catherine E Peishoff; Lon R Cardon; Jose F Garcia-Bustos
Journal:  Nature       Date:  2010-05-20       Impact factor: 49.962

5.  Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.

Authors:  R Li; R Sirawaraporn; P Chitnumsub; W Sirawaraporn; J Wooden; F Athappilly; S Turley; W G Hol
Journal:  J Mol Biol       Date:  2000-01-14       Impact factor: 5.469

6.  Lead- and drug-like compounds: the rule-of-five revolution.

Authors:  Christopher A Lipinski
Journal:  Drug Discov Today Technol       Date:  2004-12

Review 7.  Antifolate agents: a patent review (2006 - 2010).

Authors:  Dennis L Wright; Amy C Anderson
Journal:  Expert Opin Ther Pat       Date:  2011-05-27       Impact factor: 6.674

8.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening.

Authors:  P J O'Brien; W Irwin; D Diaz; E Howard-Cofield; C M Krejsa; M R Slaughter; B Gao; N Kaludercic; A Angeline; P Bernardi; P Brain; C Hougham
Journal:  Arch Toxicol       Date:  2006-04-06       Impact factor: 5.153

9.  Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.

Authors:  Joaquín Rullas; Juan Ignacio García; Manuela Beltrán; Pere-Joan Cardona; Neus Cáceres; José Francisco García-Bustos; Iñigo Angulo-Barturen
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

10.  High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity.

Authors:  Anuradha Kumar; Meng Zhang; Linyun Zhu; Reiling P Liao; Charles Mutai; Shittu Hafsat; David R Sherman; Ming-Wei Wang
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

View more
  10 in total

1.  Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.

Authors:  Behnoush Hajian; Eric Scocchera; Carolyn Shoen; Jolanta Krucinska; Kishore Viswanathan; Narendran G-Dayanandan; Heidi Erlandsen; Alexavier Estrada; Katarína Mikušová; Jana Korduláková; Michael Cynamon; Dennis Wright
Journal:  Cell Chem Biol       Date:  2019-03-28       Impact factor: 8.116

2.  Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.

Authors:  John P Santa Maria; Yumi Park; Lihu Yang; Nicholas Murgolo; Michael D Altman; Paul Zuck; Greg Adam; Chad Chamberlin; Peter Saradjian; Peter Dandliker; Helena I M Boshoff; Clifton E Barry; Charles Garlisi; David B Olsen; Katherine Young; Meir Glick; Elliott Nickbarg; Peter S Kutchukian
Journal:  ACS Chem Biol       Date:  2017-08-29       Impact factor: 5.100

Review 3.  Mycobacterium tuberculosis in the Face of Host-Imposed Nutrient Limitation.

Authors:  Michael Berney; Linda Berney-Meyer
Journal:  Microbiol Spectr       Date:  2017-06

Review 4.  Revitalizing antifolates through understanding mechanisms that govern susceptibility and resistance.

Authors:  Shannon Lynn Kordus; Anthony David Baughn
Journal:  Medchemcomm       Date:  2019-05-08       Impact factor: 3.597

5.  Identification of P218 as a potent inhibitor of Mycobacterium ulcerans DHFR.

Authors:  Gustavo P Riboldi; Rachael Zigweid; Peter J Myler; Stephen J Mayclin; Rafael M Couñago; Bart L Staker
Journal:  RSC Med Chem       Date:  2020-10-22

6.  Screening of Preselected Libraries Targeting Mycobacterium abscessus for Drug Discovery.

Authors:  Adrian Richter; Angelika Strauch; Joseph Chao; Mary Ko; Yossef Av-Gay
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

7.  Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis.

Authors:  Behnoush Hajian; Eric Scocchera; Santosh Keshipeddy; Narendran G-Dayanandan; Carolyn Shoen; Jolanta Krucinska; Stephanie Reeve; Michael Cynamon; Amy C Anderson; Dennis L Wright
Journal:  PLoS One       Date:  2016-08-31       Impact factor: 3.240

Review 8.  Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era.

Authors:  Alina Minias; Lidia Żukowska; Ewelina Lechowicz; Filip Gąsior; Agnieszka Knast; Sabina Podlewska; Daria Zygała; Jarosław Dziadek
Journal:  Front Microbiol       Date:  2021-02-02       Impact factor: 5.640

9.  8-Mercaptoguanine-based inhibitors of Mycobacterium tuberculosis dihydroneopterin aldolase: synthesis, in vitro inhibition and docking studies.

Authors:  Alexia de Matos Czeczot; Candida Deves Roth; Rodrigo Gay Ducati; Kenia Pissinate; Raoní Scheibler Rambo; Luís Fernando Saraiva Macedo Timmers; Bruno Lopes Abbadi; Fernanda Souza Macchi; Víctor Zajaczkowski Pestana; Luiz Augusto Basso; Pablo Machado; Cristiano Valim Bizarro
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

10.  Potency boost of a Mycobacterium tuberculosis dihydrofolate reductase inhibitor by multienzyme F420H2-dependent reduction.

Authors:  Wassihun Wedajo Aragaw; Brendon M Lee; Xuan Yang; Matthew D Zimmerman; Martin Gengenbacher; Véronique Dartois; Wai-Keung Chui; Colin J Jackson; Thomas Dick
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-22       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.